Buy Recommendation for Gain Therapeutics Based on Parkinson's Drug Development and Strong Financial Position

Gain Therapeutics has received a Buy recommendation from Maxim Group analyst Jason McCarthy due to its promising Parkinson's drug development and strong financial position. McCarthy cites the company's lead drug candidate, GT-02287, and its potential to modulate glucocerebrosidase activity, as well as recent equity financing that ensures financial runway. McCarthy's valuation model supports a favorable price target of $5.00.

Gain Therapeutics, Inc. (GANX) has received a Buy recommendation from Maxim Group analyst Jason McCarthy, highlighting the company's promising Parkinson's drug development and strong financial position. McCarthy cited the company's lead drug candidate, GT-02287, and its potential to modulate glucocerebrosidase activity, along with recent equity financing that ensures financial runway. McCarthy's valuation model supports a favorable price target of $5.00.

Financial Performance
For the second quarter of 2025, Gain Therapeutics reported a net loss of $0.19 per share, a significant improvement from the $0.42 per share loss in the same period last year. Research and Development (R&D) expenses decreased by $1.7 million to $2.8 million, primarily due to research grant income and tax incentives. General and Administrative (G&A) expenses also saw a reduction, decreasing by $1.4 million to $2.3 million, mainly due to lower stock-based compensation costs. As of June 30, 2025, the company had $6.7 million in cash and cash equivalents, down from $10.4 million at the end of 2024 [1].

Clinical Milestones
Gain Therapeutics reached full enrollment for its Phase 1b study evaluating GT-02287 in Parkinson’s Disease (PD) with or without GBA1 mutations earlier than anticipated. The analysis of functional changes and biomarker activity at 90 days is expected to be available during the fourth quarter of 2025. The company has also submitted a request to extend the dosing duration of the Phase 1b study beyond the current 90 days [2].

Funding and Strategic Initiatives
In July 2025, following the close of the second quarter, Gain Therapeutics completed an underwritten public offering that resulted in approximately $7.1 million of net proceeds. This funding is expected to support the company’s ongoing clinical trials and extend its cash runway beyond the completion of the Phase 1b study [2].

Future Outlook
Gain Therapeutics anticipates the analysis of functional changes and biomarker activity from the Phase 1b study to be available in the fourth quarter of 2025. The company also expects to receive approval from healthcare authorities in Australia to extend the dosing duration for participants in the Phase 1b study. Additionally, an IND submission to the FDA is expected by the end of 2025, facilitating the expansion of Phase 2 clinical development for GT-02287 to include clinical sites in the United States [1].

References
[1] https://www.tradingview.com/news/tradingview:8f745371fbf2a:0-gain-therapeutics-reports-financial-results-for-second-quarter-2025/
[2] https://gaintherapeutics.com/newsroom/press-releases/press-releases-2025/gain-therapeutics-reports-financial-results-for-second-quarter-2025-and-provides-corporate-update/